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PotassiumAlzheimer's disease (AD) is associated with impaired glutamate clearance and depressed Na+/K+ ATPase
levels in AD brain that might lead to a cellular ion imbalance. To test this hypothesis, [Na+] and [K+] were
analyzed in postmortem brain samples of 12 normal and 16 AD individuals, and in cerebrospinal ﬂuid
(CSF) from AD patients and matched controls. Statistically signiﬁcant increases in [Na+] in frontal (25%)
and parietal cortex (20%) and in cerebellar [K+] (15%) were observed in AD samples compared to controls.
CSF from AD patients and matched controls exhibited no differences, suggesting that tissue ion imbalances
reﬂected changes in the intracellular compartment. Differences in cation concentrations between normal
and AD brain samples were modeled by a 2-fold increase in intracellular [Na+] and an 8–15% increase in in-
tracellular [K+]. Since amyloid beta peptide (Aβ) is an important contributor to AD brain pathology, we
assessed how Aβ affects ion homeostasis in primary murine astrocytes, the most abundant cells in brain tis-
sue. We demonstrate that treatment of astrocytes with the Aβ 25–35 peptide increases intracellular levels of
Na+ (~2–3-fold) and K+ (~1.5-fold), which were associated with reduced levels of Na+/K+ ATPase and the
Na+-dependent glutamate transporters, GLAST and GLT-1. Similar increases in astrocytic Na+ and K+ levels
were also caused by Aβ 1–40, but not by Aβ 1–42 treatment. Our study suggests a previously unrecognized
impairment in AD brain cell ion homeostasis that might be triggered by Aβ and could signiﬁcantly affect elec-
trophysiological activity of brain cells, contributing to the pathophysiology of AD.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD), the most prevalent form of dementia, is
a neurodegenerative disorder characterized by the presence of neuro-
ﬁbrillary tangles, dystrophic neurites and senile plaques composed
predominantly of amyloid beta peptide (Aβ) derived from the amy-
loid precursor protein [1]. Aβ is 37–43 amino acids in length and res-
idues 25–35 in the Aβ peptide are the most toxic [2]. Among other
biochemical aberrations, elevated levels of reactive oxygen species
[3], impaired glutamate clearance [4], and depressed Na+/K+ ATPase
levels [5] have been reported in AD brain. Also, a decrease in Na+/K+
ATPase activity and protein levels was observed in hippocampus ofβ peptide; CAβ42, levels of Aβ
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rights reserved.APP+PS1 transgenic mice, a model for AD [6]. These biochemical
effects suggest changes in antioxidant capacity, glutamate-based neu-
rotransmission and in membrane polarization–repolarization, pro-
cesses interconnected at a single metabolic hub. We hypothesized
that in AD, impairments in the interconnections extending across as-
trocytes and neurons linking sulfur metabolism to glutamate-based
neurotransmission and ion homeostasis, propagate through this
intercellular network and result in coordinated changes in redox
and ion regulation affecting both cell types.
Astrocytes are organized in extensive networks poised to dynam-
ically inﬂuence neuronal function. The metabolic dependence of neu-
rons on astrocytes renders them vulnerable to astrocytic dysfunction,
which can exacerbate neuronal damage under pathological condi-
tions [7,8]. Glutathione (GSH) is a major antioxidant in brain whose
synthesis is limited by the availability of cysteine [9]. The latter can
be synthesized from methionine via the transsulfuration pathway,
or derived from imported cystine, which is reduced subsequent to
its transport. The twin transporters, xC− and XAG− , link GSH metabolism
to the glutamate–glutamine cycle and connect in turn to Na+/K+
ATPase [10,11]. The XAG− system (also known as EAAT transporters)
clears glutamate released during synaptic transmission using the so-
dium gradient in a process that translocates 3Na+ (in) and one
K+(out) for every glutamate that is imported into the cell [12].
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untreated controls [13,14] and have a disturbed redox status [15]. Ox-
idative modiﬁcation and impaired functioning of GLT-1 have been
reported in AD brain and in Aβ-treated synaptosomes [4]. Glutamate
uptake activates the Na+/K+ ATPase, which works to normalize the
resting transmembrane ion gradients. Protein levels and the activity
of the Na+/K+ ATPase are reported to be lower in AD brains com-
pared to age-matched controls [5]. The glutamate gradient in turn
drives the xC− antiporter, which exchanges extracellular cystine for in-
tracellular glutamate in a stoichiometric process [10]. Expression of
this antiporter decreases in Aβ treated astrocytes [15]. In addition to
using the transmembrane sodium gradient, which drives the trans-
port of glutamate and other metabolites, astrocytes take up potassi-
um ions released during the repolarizing phase of action potentials
[16] and changes in the astrocytic membrane potential can inﬂuence
neuronal ﬁring rates [17].
Heterocellular coupling between astrocytes and neurons is indis-
pensable for cycling glutamate, and for redox and ion balance. Impair-
ment at one or more key network nodes in either cell type is expected
to have pleiotropic consequences. While perturbations in astrocytic
redox balance [15,18] and glutamate clearance [13,14] in response
to Aβ have received some attention, little is known about the effects
of Aβ on the astrocytic cation inventory, which might in turn inﬂu-
ence ion conductance changes that underlie many aspects of neuronal
function.
To test the hypothesis that impaired glutamate clearance and de-
pressed Na+/K+ ATPase levels observed in AD brain are associated
with Na+ and K+ imbalances, we analyzed Na+ and K+ levels in
postmortem brain tissues of normal and AD individuals as well as in
cerebrospinal ﬂuid (CSF) of AD patients and matched controls. Signif-
icant ion imbalances were found in the cortical (Na+) and cerebellar
(K+) specimens of AD brain but not in CSF of AD subjects, suggesting
that the observed changes in tissue samples reﬂect changes in the in-
tracellular pool. Mathematical modeling of the experimental data
showed that the observed differences in ion concentrations between
normal and AD brain tissues can be explained by a 2-fold increase
in intracellular [Na+] and a 8–15% increase in intracellular [K+] in
AD individuals. To assess whether Aβmight be responsible for the ob-
served ion imbalance in brain cells, we analyzed the effect of Aβ on
Na+ and K+ concentrations in cultured primary mouse astrocytes,
which are the most abundant cell type in brain. We found that treat-
ment of astrocytes with Aβ 25–35 increased intracellular [Na+] (~2–
3-fold) and [K+] (~1.5-fold), which is similar to the increase in intra-
cellular Na+ and K+ levels observed in brain tissues of AD individuals.
Similar ion imbalances were observed in astrocytes treated with Aβ
1–40, but not with Aβ 1–42. We speculate that ion imbalance in AD
brain might result at least in part, from ion imbalance in astrocytes,
which, in turn, might be induced by Aβ. To our knowledge, this
study provides the ﬁrst evidence for signiﬁcant perturbation of ion
homeostasis in AD brain, which could be important for the patho-
physiology of brain dysfunction in AD.
2. Materials and methods
2.1. Human brain and CSF samples
AD brain and age-matched control samples were from theMichigan
Alzheimer's disease Research Center Brain Bank. AD samples were de-
rived from clinically well-characterized individuals participating in a
prospective brain collection program. At death, one hemisphere was
cut into 1–1.5 cm coronal slabs and frozen rapidly over liquid N2
vapor. The other hemispherewas ﬁxed in 10% neutral buffered formalin
and used for neuropathologic analysis. All specimens are reviewed by
the same neuropathologist and diagnosis was established by the
Reagan-NIA criteria [19]. Slabs were stored in heat-sealed freezer bags
at −80 °C until the time of tissue use. Age, gender, and post-mortemdelay matched control specimens were derived from individuals with
no clinical history of neurologic disease and normal neuropathologic
examinations. Slabs were warmed to−20 °C and blocks of frontal cor-
tex, parietal cortex, and cerebellum were prepared. The collection of
human brain tissues was approved by the University of Michigan Med-
ical School Institutional ReviewBoard. CSF samples fromnon-demented
individuals (clinical dementia rating (CDR) 0) and those with verymild
to moderate Alzheimer's dementia (CDR 0.5–2) [20] were obtained
from theWashington University's Alzheimer's Disease Research Center.
Data for CSF levels of Tau, Ptau181, and Aβ 1–42 and data for PIB bind-
ing were obtained from the Washington University Biomarker and Im-
aging Cores, respectively. Details of these procedures have been
published previously [21].
2.2. Cell culture
U-87MG (human astrocytoma), Jurkat (human T cell leukemia)
and HEK293 (human embryonic kidney) cells were obtained from
ATCC. All transformed cell lines were cultured with 100% medium
change in 6-well plates with 2 mL medium per well. The following
media were used for cultures of transformed cell lines: EMEM
(ATCC) for U-87 MG cells, DMEM (Invitrogen) for HEK 293 cells and
RPMI-1640 (Invitrogen) for Jurkat cells. All media contained 10% nor-
mal FBS (Hyclone), 100 units/mL penicillin and 100 μg/mL strepto-
mycin (Invitrogen).
2.3. Isolation and culture of murine astrocytes
Primary murine cortical astrocyte cultures were prepared from 1
to 2 day old Balb/C pups as described previously [22,23]. At the end
of the third passage, cells were seeded in 6-well (1–2×106 cells/
well/2 mL) or 12-well (1×106 cells/well/1 mL) plates and used for
experiments after two days. DMEM/F12 mixture containing 10%
heat-inactivated FBS, 2 mM additional L-glutamine, 100 units/mL
penicillin and 100 μg/mL streptomycin was used as a complete medi-
um for astrocyte cultures. The purity of astrocytes was determined as
described previously [23] and was ≥93%. The protocols used for han-
dling animals were approved by the University Committee on Use
and Care of Animals, University of Michigan.
2.4. Aggregation of Aβ peptide
The lyophilized forms of the triﬂouroacetate salt of the human Aβ
25–35, Aβ 1–40, Aβ 1–42, and the reversed Aβ 35–25 peptide
(Bachem) were aggregated as described previously [24]. Brieﬂy, Aβ
was dissolved in sterile double-distilled water as a 2 mM stock solu-
tion, incubated for 8 days at 37 °C and stored in aliquots at −80 °C.
Formation of aggregates was evident from the turbidity of the solu-
tion and by observation under a light microscope.
2.5. Aβ treatment of cell cultures
U-87MG and HEK 293 cells were used for experiments at 80–90%
conﬂuency. Jurkat cells were used at a cell density of 2×106 cells/well.
At the beginning of each experiment, 100% medium was changed and
aggregated Aβ 25–35was added to a ﬁnal concentration of 50 μM (con-
centration estimated prior to aggregation). Cells were collected for ion
analysis after 24 h of incubation with Aβ as described below.
Astrocytes were treated acutely or repeatedly with Aβ 25–35 and
Aβ 35–25. Aβ 1–40 and Aβ 1–42 were only used in acute treatments.
A single bolus of Aβwas added for acute treatment and samples were
collected 24 h later. For the repeated treatment model, Aβwas added
3 times at 72 h intervals and samples were collected 24 h after the
last treatment. Each time, Aβ was added to astrocytes after 100%
change of the complete medium. In each independent experiment
(using different preparations of astrocytes), cells were cultured in
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each well was prepared and analyzed separately and the data were
averaged. Cell death was observed in b10% of cells in culture follow-
ing acute or repeated Aβ treatment and was comparable to that
seen in the control cell culture as reported previously [15]. Cell
death was monitored by the PI-AV labeling kit (BioVision) and the
TUNEL assay kit (Roche) according to the vendor's protocols (data
not shown).
Ouabaine (500 μM), aspartate β-hydroxamate (400 μM), furosemide
(2 mM), bumetanide (10 μM), and dimethyl amiloride (50 μM) (Sigma)
when used, were added to astrocytes exposed to repeated treatment
with 50 μM Aβ 25–35 at the time of the last Aβ treatment, and cells
were collected for ion analysis 24 h later.
2.6. Metabolite analysis
Frozen brain tissue (~100 mg) was pulverized in liquid N2 and the
resulting powder (~50 mg) was added to pre-weighed tubes
containing 300 μL of 6% TCA (to precipitate protein) for glutamine
and methionine analysis or 300 μL of metaphosphoric acid solution
(16.8 mg/mL HPO3, 2 mg/mL EDTA and 9 mg/mL NaCl, to precipitate
protein) for glutamate analysis. The tubes were weighed again to de-
termine the wet weight of the added tissue and then stored at −
80 °C until further analysis. CSF samples were mixed with an equal
volume of 10% TCA or metaphosphoric acid solution and stored at
−80 °C until further analysis.
Glutamate concentration in CSF and brain sampleswasmeasured by
HPLC with 2,4-dinitroﬂuorobenzene derivatization initially described
for thiol analysis [25]. Concentrations of glutamine and methionine
were measured by HPLC using o-phthaldialdehyde derivatization [25].
2.7. Western blot analysis
Astrocytes were collected for Western blot analysis after 24 h of
acute treatment or the last repeated treatment with 50 μM of Aβ
25–35. Samples were prepared as described previously [26]. Anti-
bodies against GLAST (EAAT1) (Millipore), GLT-1 (Santa Cruz Bio-
tech), Na+/K+ ATPase α1 (Santa Cruz Biotech) and actin (Sigma)
were used to monitor expression of the respective protein antigens
and were detected using the Dura chemiluminescent horseradish
peroxidase system (Pierce) according to the vendor's protocol. For
quantiﬁcation of Western blot data, the integrated intensity of pro-
tein band of interest was measured using ImageJ software and nor-
malized to the integrated intensity of the actin band in the same
samples.
2.8. Measurement of cations
Frozen brain samples (~100 mg) were added to a pre-weighed
plastic tube containing 300 μL of deionized water, and the tubes
re-weighed. Tissue was homogenized with a plastic pestle on ice,
centrifuged at 15,000×g for 5 min and the supernatant was used
for Na+ and K+ ion analysis using a ﬂame photometer. CSF samples
were used for ion analysis without any modiﬁcations. To analyze
Na+ and K+ in cells pre-exposed to Aβ, culture medium was aspirat-
ed and stored frozen until analysis of the ions in the medium. Cells
were washed twice with cold choline chloride solution (150 mM),
and re-suspended in 100 μL of choline chloride solution. The cell sus-
pension was freeze–thawed 3 times, cell membranes were removed
by centrifugation and ion concentrations in the resulting supernatant
were measured using a ﬂame photometer. To measure protein con-
centration, ~30 μL of the cell suspension was mixed with an equal
volume of lysis buffer and protein content was measured using the
Bradford method as described previously [25]. The resulting ion con-
centrations were normalized to protein concentration in the cellsuspension or normalized to the amount of tissue and presented as
mmoles per g of protein or mmoles per kg of tissue, respectively.
2.9. Mathematical model for correlating total, intracellular and extracellular
brain [Na+] and [K+]
To estimate intracellular concentrations of Na+ and K+ in brain
samples using total (measured) concentration of ions in the tissue,
we developed the following model.
Total tissue concentrations of Na+ and K+ are described by
Eqs. (1) and (2) for mass conservation:
Nat ¼ NainV in þ NaexVexð Þ= V in þ Vexð Þ ð1Þ
Kt ¼ K inV in þ KexVexð Þ= V in þ Vexð Þ: ð2Þ
Here Nat and Kt denote total (measured) Na+ and K+ concentra-
tions in tissue, Nain, Naex, Kin, and Kex denote intracellular and extra-
cellular Na+ and K+ concentrations respectively, and Vin, and Vex
denote cell volume and extracellular volume in the tissue. The cell
volume includes total volume occupied by all cells in the tissue sam-
ple and extracellular volume includes all extracellular compartments
(interstitial liquid, CSF, blood plasma, etc.) in the sample.
For unit volume (Vin+Vex=1), Eqs. (1) and (2) transform to the
following form:
Nat ¼ NainV in þ Naex 1−V inð Þ ¼ Naex þ Nain−Naexð ÞV inð ð3Þ
Kt ¼ K inV in þ Kex 1−V inð Þ ¼ Kex þ K in−Kexð ÞV in:ð ð4Þ
Here Vin and Vex are fractions of the tissue volume corresponding
to cell and extracellular volumes.
Eqs. (3) and (4) indicate that total tissue concentrations of Na+
and K+ are linear functions of the relative cell volume. As a conse-
quence, the total K+ concentration in samples of the same tissue
with different relative cell volumes must be a linear function of
total Na+ concentration. These equations show that if intracellular
and extracellular ion concentrations are constant, then an increase in
the cell volume fraction in a tissue causes a linear decrease in total
(measured) Na+ concentration (because Nain−Naex b0), and a linear
increase in total (measured) K concentration (because Kin−Kex >0).
Next, using Eq. (3) one can express Vin as a function of Nat:
V in ¼ Nat−Naexð Þ= Nain−Naexð Þ: ð5Þ
By replacing Vin in Eq. (4) with the function in Eq. (5), we obtain
the following equation:
Kt ¼ Kex þ K in−Kexð Þ Nat−Naexð Þ= Nain−Naexð Þ
¼ Kex þ Kex−K inð ÞNaex þ K in−Kexð ÞNatð Þ= Nain−Naexð Þ: ð6Þ
This equation reveals the linear dependence of total K+ concen-
tration on total Na+ concentration in tissue samples if intracellular
and extracellular Na+ and K+ concentrations are constant and the
cell volume fraction in samples varies. Eq. (6) can be rewritten in
the following form:
Kt ¼ Aþ B  Nat ð7Þ
A ¼ Kex þ Kex−K inð ÞNaex= Nain−Naexð Þ ð8Þ
B ¼ K in−Kexð Þ= Nain−Naexð Þ: ð9Þ
Eqs. (6)–(9) can be used to estimate intracellular tissue Na+ and
K+ concentrations using total concentrations of Na+ and K+.
Table 2
Average ion and metabolite concentrations in brain samples from AD patients and
age-matched controls.a
Parameter Subjects Frontal
cortex
p Parietal
cortex
p Cerebellum p
Sodium
(mmol/kg
tissue)
Normal 73.9±11.2 0.01 71.1±8.0 0.01 68.9±11.5 0.05
AD 92.1±20.8 85.0±14.9 79.4±14.6
Potassium
(mmol/kg
tissue)
Normal 60.7±8.0 0.38 63.7±6.5 0.46 68.4±10.0 0.02
AD 57.7±9.2 66±9.2 76.2±7.4
Glutamine
(mmol/kg
tissue)
Normal 6.82±3.99 0.82 6.98±3.98 0.82 7.99±2.63 0.78
AD 6.57±1.76 7.29±2.96 8.26±2.43
Glutamate
(mmol/kg
tissue)
Normal 9.0±1.7 0.08 9.2±1.6 0.13 10.9±3.4 0.68
AD 10.5±2.6 10.7±2.9 11.4±3.0
Methionine
(μmol/kg
tissue)
Normal 231±93 0.56 257±97 0.54 474±244 0.01
AD 204±132 305±257 262±105
a The number of samples in each group was as follows: AD (n=16) and controls
(n=12) and the data represent the mean±SD.
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Statistical analysis and linear ﬁts of experimental data were done
using Origin 7 software (OriginLab). Comparison between groups
was done using Student's t test. p≤0.05 was considered as the crite-
rion for signiﬁcant difference.
3. Results
3.1. Ion imbalances in AD brain
Tissue Na+ and K+ concentrations were determined in human
postmortem brain samples of frontal cortex, parietal cortex, and cer-
ebellum from 16 AD subjects and 12 age-matched controls (Table 1).
On average, frontal and parietal cortical regions from AD subjects
were found to exhibit signiﬁcantly higher tissue Na+ concentrations,
while cerebellum, a region with lower amyloid pathology, exhibited
a non-signiﬁcant trend towards higher tissue Na+ concentrations
(Table 2). The average K+ concentrations in frontal and parietal cor-
tex samples of AD patients were not signiﬁcantly different from K+
concentrations in similar samples of control individuals, while K+
concentrations in cerebellum samples of AD patient were signiﬁ-
cantly increased (Table 2). Differences in ion concentrations be-
tween AD and healthy subjects did not correlate with sex, age and
postmortem time of the individual specimens (Table 1, Fig. S1).
In principle, the observed elevation in Na+ concentration in AD
brain samples could reﬂect increases in Na+ concentration of either
the intra- or the extra-cellular (blood, CSF, interstitial) compartment
or an increase in the relative size (i.e. volume) of the extracellular
(Na+-rich) compartment. An increase in the relative extracellularTable 1
Postmortem [Na+] and [K+] values in brain tissue of normal individuals and AD patients.
Patient ID Diagnosis Sex Age
(years)
Postmortem time
(h)
1 Normal M 91 8
2 Normal F 86 18
3 Normal F 95 18
4 Normal M 81 6
5 Normal M 77 17
11 Normal F 48 5
12 Normal M 73 7
13 Normal F 73 13.5
14 Normal M 73 18
15 Normal M 70 20.5
16 Normal M 72 23
17 Normal M 83 28
Normal mean 77 15
Normal SD 12 7
6 AD M 90 3
7 AD F 82 6
8 AD M 75 7
9 AD M 83 7
10 AD F 89 20
18 AD M 73 3
19 AD M 83 7
20 AD M 77 7.75
21 AD M 76 8
22 AD F 75 8
23 AD F 78 8
24 AD M 83 8
25 AD F 66 9
26 AD F 94 9
27 AD M 65 11
28 AD F 78 24
AD mean 79 9
AD SD 8 5
pb 0.54 0.02
a FC—frontal cortex, PC—parietal cortex, Cb—cerebellum.
b Parameter of statistical signiﬁcance for the difference between normal and AD mean vavolume has been reported in a mouse AD model [27]. To assess
whether ion concentrations change in the extracellular compartment
of AD brain tissue, we analyzed Na+ and K+ concentrations in CSF
samples from clinically characterized AD subjects and matched con-
trols (Table 3). No difference in Na+ or K+ concentrations between
the two groups was observed (Table 3). Also, no difference in CSF
Na+ or K+ concentrations was observed between males and females
(Table S1). Thus, the increase in Na+ in AD post-mortem tissue sam-
ples (Table 2) likely does not reﬂect changes in the composition of the[Na]
(mmol/kg tissue)
[K]
(mmol/kg tissue)
FCa PC Cb FC PC Cb
61.7 72.0 73.2 63.5 74.1 63.5
76.0 82.8 59.5 58.4 62.7 76.4
69.4 61.5 81.0 60.5 65.5 55.0
75.6 74.5 75.6 62.3 57.7 64.1
89.7 60.1 76.3 49.7 62.7 62.9
55.9 60.8 78.8 73.5 75.4 64.6
79.2 67.2 65.9 60.4 68.9 61.3
88.1 81.9 56.4 63.1 62.7 89.0
63.6 69.4 50.2 72.0 54.6 79.9
62.5 70.3 57.2 65.6 60.4 76.5
78.8 72.1 87.3 50.4 62.3 58.7
85.7 80.7 65.6 48.5 57.0 68.9
73.9 71.1 68.9 60.7 63.7 68.4
11.2 8.0 11.5 8.0 6.5 10.0
68.7 76.1 65.7 72.0 59.0 68.9
131.2 101.0 103.9 56.5 73.1 77.1
68.4 70.6 63.2 61.8 70.3 74.5
87.8 93.5 61.5 63.5 59.0 80.1
104.3 100.3 84.7 55.2 60.8 69.6
77.1 64.3 58.3 60.6 74.7 83.3
85.3 81.1 92.1 56.2 72.5 70.8
73.3 66.3 63.8 67.4 63.3 81.4
79.5 90.8 88.5 69.8 70.2 81.8
103.4 97.2 81.1 46.2 60.1 77.3
73.4 84.1 66.8 67.9 62.1 81.1
89.1 72.3 88.6 59.4 75.3 68.9
111.5 112.7 103.7 43.9 41.6 60.8
81.9 72.7 80.7 50.4 79.6 72.4
104.2 74.9 83.7 48.0 67.3 80.8
134.6 102.9 83.8 44.2 66.5 90.9
92.1 85.0 79.4 57.7 66.0 76.2
20.8 14.9 14.6 9.2 9.2 7.4
0.01 0.01 0.05 0.38 0.46 0.02
lues.
Table 3
Parameters for individual CSF samples, mean and SD values for controls (1–15A) and AD patients (1–15B) used in this study.
ID Sex Age at lumbar puncture
(years)
CDRa PIBb Tauc
(pg/ml)
Ptau181d
(pg/ml)
CAβ42e
(pg/ml)
Na
(mM)
K
(mM)
Gln
(μM)
Glu
(μM)
Met
(μM)
1A F 66 0 neg 161 28 733 143 2.68 474 4.40 5.46
2A F 71 0 neg 214 32 913 146 2.82 539 2.88 5.78
3A M 75 0 neg 258 48 722 144 2.89 559 3.38 6.76
4A M 66 0 neg 285 44 959 144 2.84 545 2.93 9.41
5A M 83 0 neg 322 46 860 145 2.78 532 2.76 6.56
6A F 76 0 neg 624 100 1109 147 2.89 574 2.76 7.74
7A M 71 0 neg 249 55 844 147 2.86 517 2.71 5.01
8A F 81 0 neg 330 60 1074 147 2.82 487 2.40 4.81
9A F 67 0 neg 443 86 1081 147 2.69 511 3.73 4.64
10A F 69 0 neg 190 41 762 143 2.92 488 3.27 4.77
11A M 75 0 neg 375 94 736 143 2.72 514 3.70 6.40
12A F 75 0 neg 400 62 931 149 2.89 532 3.57 5.74
13A M 70 0 neg 177 39 1056 147 3.06 631 3.59 7.94
14A F 72 0 neg 214 45 1089 149 2.80 580 3.49 5.70
15A M 75 0 neg 402 84 1293 144 2.82 774 3.87 10.59
Normal mean 73 310 58 944 146 2.83 550 3.30 6.48
Normal SD 5 125 23 170 2 0.10 74 0.54 1.76
1B F 73 0f pos 1068 181 326 144 2.72 579 2.96 6.40
2B F 74 2 pos 963 121 426 150 2.85 560 2.92 6.52
3B F 82 0.5 pos 929 133 321 146 2.97 574 2.55 7.94
4B F 65 0.5 pos 481 63 342 149 2.76 544 2.76 5.78
5B F 81 0.5 – 490 73 391 147 3.03 536 2.74 5.13
6B M 83 0.5 – 645 76 391 148 2.76 509 2.65 6.31
7B F 78 0.5 pos 401 58 294 146 2.81 625 2.30 6.76
8B F 75 0.5 – 578 78 241 144 2.77 485 2.52 5.17
9B F 82 0f pos 631 88 233 143 2.76 775 3.68 8.15
10B M 80 0.5 – 569 98 410 146 2.68 645 3.28 7.74
11B F 80 0f pos 440 74 319 148 2.75 548 3.33 5.58
12B M 77 0.5 – 307 50 321 147 2.73 538 3.08 6.19
13B M 74 0.5 – 516 68 202 147 2.77 494 3.16 5.25
14B F 72 0.5 – 1204 159 393 148 2.73 449 2.93 5.50
15B F 72 0.5 – 650 165 312 149 2.85 509 3.14 5.54
AD Mean 77 658 99 328 147 2.80 558 2.93 6.26
AD SD 5 262 42 67 2 0.10 79 0.36 1.01
pg 0.051 10−4 0.0024 10−12 0.17 0.31 0.79 0.04 0.67
a CDR: clinical dementia rating.
b PIB: results of [11C]-Pittsburgh B compound positron emission tomography (PET) imaging.
c Tau: CSF tau levels.
d Ptau181: CSF phospho-tau 181 levels.
e CAβ42: levels of Aβ 1–42 peptide in CSF.
f Subjects with CDR = 0 are interpreted to be preclinical AD on the basis of positive PIB PET imaging and low CSF Aβ42 levels. Subjects with CDR >0 belong to the AD group.
g p: parameter of statistical signiﬁcance for the difference between control and AD mean values.
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volume in AD brain tissue is also inconsistent with the negligible de-
crease in tissue K+ levels in AD frontal cortex samples and the slight
increase in tissue K+ levels in parietal cortex and cerebellum samples.
An increase in the relative extracellular volume is expected to result
in a signiﬁcant decrease in K+ levels since the extracellular [K+]≪
intracellular [K+]. Based on these lines of reasoning, we conclude
that the ion imbalance observed in AD brain tissue is likely to reﬂect
intracellular ion perturbations.3.2. Comparison of glutamate levels between AD and normal subjects
Estimates of glutamate levels in AD versus control brain have pro-
duced contrasting results [28–30]. We measured the glutamate con-
centration in human brain homogenates and in the CSF. Although
slightly higher glutamate levels were observed in all three regions
from AD versus control brain samples, the difference did not reach
statistical signiﬁcance (Table 2). In CSF, a modest decrease in gluta-
mate concentration was observed in clinically characterized AD sub-
jects compared to normal controls (Table 3). Differences were not
seen in two other metabolites linked to this metabolic hub, methio-
nine and glutamine, in AD versus control cortical samples or in CSF
samples, while a signiﬁcant decrease in methionine was observed in
AD cerebellar samples versus controls (Tables 2 and 3).3.3. Aβ induces Na+ and K+ ion imbalances in astrocytes
Astrocytes are the most abundant cells in the brain. To assess
whether the ion imbalances seen in brain tissue could be induced
by Aβ, we treated primary mouse astrocytes with Aβ 25–35. In re-
sponse to this treatment, an increase in both intracellular Na+ and
K+ contents was observed in astrocytes, which was dependent on
Aβ concentration (Fig. 1). No changes were observed in the concen-
trations of these ions in the culture medium. The reverse and inactive
Aβ 35–25 peptide had no effect on the cellular Na+ and K+ contents
(Fig. 1). At 50 μM Aβ 25–35 concentration, where a maximal effect
was observed, intracellular Na+ increased ~1.8- and ~2.6 fold while
K+ increased ~1.4- and ~1.6 fold following acute and repeated Aβ
treatment, respectively (Fig. 2a).
The Na+/K+ ATPase is primarily responsible for maintaining the
Na+ and K+ ion gradients across the plasma membrane and the
large ion imbalance observed with Aβ treatment suggested impaired
activity of this protein. Western blot analysis showed lower Na+/K+
ATPase levels in astrocytes that were either acutely or repeatedly
treated with Aβ 25–35, with the effect being more signiﬁcant in the
latter case (Fig. 2b, c). The decrease in Na+/K+ ATPase expression
cannot by itself account for the simultaneous increase in intracellular
Na+ and K+ contents since inhibition of astrocytic Na+/K+ ATPase
with ouabain caused increased intracellular Na+ while concomitantly
decreasing intracellular K+ levels (Fig. 3). Addition of ouabain to Aβ
Fig. 1. The effect of different concentrations and forms of Aβ 25–35 on intracellular levels of Na+ and K+ in primary mouse astrocytes. Cells were treated acutely (gray bars) or
repeatedly (black bars) with different concentrations of Aβ 25–35 or with 50 μM of Aβ 35–25 and intracellular Na+ (a) and K+ (b) levels were measured 24 h after acute or
the last repeated Aβ treatment as described under Materials and methods. White bars represent data for control i.e. untreated cells. Data are representative of 2 independent ex-
periments (with different cell preparations) each performed in triplicate. The bars represent the mean±SD.
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K+ levels decreased to the levels of ouabain treated controls.
Since the transport of glutamate and the cations, Na+ and K+,
across the plasma membrane is functionally linked, we next exam-
ined the effect of Aβ 25–35, if any, on the levels of the astrocytic
XAG− transporters, GLAST and GLT-1, which were reduced with repeat-
ed but not acute Aβ 25–35 treatment (Fig. 4).
Treatment of astrocytes with one of the following inhibitors: as-
partate β-hydroxamate (for XAG− ), furosemide and bumetanide (for
Na/K/Cl co-transport), and dimethyl amiloride (for Na/H exchange),
did not signiﬁcantly inﬂuence the cation balance in control cells or af-
fect the cation imbalance in Aβ 25–35 treated cells (data not shown).
These results suggest that the corresponding transporters are proba-
bly not involved in the ion imbalance induced by Aβ treatment of
astrocytes.
The effect of Aβ 25–35 treatment on intracellular Na+ and K+ levels
is cell speciﬁc. While the human astrocytoma cell line, U-87MG,
responded like astrocytes to Aβ treatment, the human embryonic kid-
ney epithelial cell line, HEK 293 cells and human T cell leukemia line,
Jurkat cells showed no effect (Fig. 5).
We also examined the effects of aggregated Aβ peptides with longer
sequences, 1–40 and 1–42, on Na+ and K+ levels in cultured mouse pri-
mary astrocytes.While Aβ 1–42 did not elicit detectable changes in astro-
cytic ion balance (data not shown), Aβ 1–40 resulted in a
concentration-dependent increase in intracellular Na+ and K+ levels
(Fig. 6), similar to that observed with Aβ 25–35.Fig. 2. Changes in ion levels and in the Na+/K+ ATPase expression in astrocytes treated with
to acute (gray bar) or repeated (black bar) treatment with Aβ 25–35, and Na+ and K+ level
Materials and methods. Data are the mean±SD of 7 independent experiments. (b) Weste
shown is representative of three independent experiments. (c) Quantiﬁcation of Na+/K+ A
α1 subunit in astrocytes treated as in (a). Data are mean±SEM obtained in three independe
difference between the corresponding vertical bars.4. Discussion
In this study, we have found differences between Na+ and K+ con-
centrations in postmortem tissue samples from different segments of
AD brain compared to controls and this difference is not reﬂected in
CSF Na+ and K+ concentrations in these two groups. While ion gradi-
ents between cells and extracellular compartments disappear after
death and intracellular and extracellular Na+ and K+ concentrations
equilibrate, the total ion content in a tissue should not be affected be-
cause ions are not metabolized and there is no ion exchange with
other tissues because of lack of blood circulation. Indeed, the absence
of a pronounced correlation between postmortem time of brain collec-
tion and tissue ion content (Table 1) conﬁrms that total brain tissue ion
content does not change postmortem. A recent study using in vivoMRI
sodium imaging revealed that hippocampal formations of AD patients
had modestly (~10%) higher [Na+] versus controls [31], which is con-
sistent with our ﬁnding of ion imbalance in other brain regions. The in-
creased Na+ concentration was suggested to be primarily within the
intracellular compartment [31]. Since intracellular [Na+] is >10-fold
lower than the extracellular [Na+], even small changes in a total tissue
[Na+] are expected to be associated with a signiﬁcant change in intra-
cellular [Na+].
After excluding the possibility that extracellular ion concentrations
contribute to the difference in ion content between normal and AD
brain tissue, two other mechanisms were considered: (i) a decrease in
the relative cell volume in AD tissue or (ii) an increase in intracellularAβ 25–35. (a) Primary mouse astrocytes were either untreated (white bar) or exposed
s were measured 24 h after acute or the last repeated Aβ treatment as described under
rn blot analysis of Na+/K+ ATPase α1 subunit in astrocytes treated as in (a). The blot
TPase Western blot data. Vertical bars show the relative expression of Na+/K+ ATPase
nt experiments. Numbers above the horizontal lines show statistical signiﬁcance of the
Fig. 3. Effects of ouabain inhibition of Na+/K+ ATPase on intracellular cation levels in
astrocytes treated with Aβ 25–35. Primary murine astrocytes were cultured without
Aβ (white bars) or repeatedly treated with 50 μM Aβ 25–35 (gray bars) as described
under Materials and methods. Ouabain was added to the incubation medium to a
ﬁnal concentration of 500 μM at the time of the last treatment with Aβ. Intracellular
(a) Na+ and (b) K+ levels were measured 24 h later as described under Materials
and methods. Data are the mean±SD (n=3).
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more detail in the following section, we note that it alone cannot explain
an increase in tissue [Na+] without a corresponding decrease in [K+] or
explain the observed increase in cerebellar [K+]. In the ﬁrst mechanism
i.e., a decrease in the relative cell volume in AD brain tissue with a con-
comitant increase in the extracellular volume, the total Na+ concentra-
tion is predicted to increase since the extracellular Na+ concentration
is >10-fold higher than its intracellular concentration. The increase in
total Na+ concentration in individual samples should be correlated
with a decrease in total tissue K+ concentration since extracellular K+
concentration is many-fold lower than its intracellular concentration.
To assess this correlation we have employed a mathematical model
(Eqs. (1)–(9)). The model predicts that if intracellular and extracellular
[Na+] and [K+] are constant and only the cell volume fraction in samples
vary, then the total tissue K+ concentration will decrease linearly withFig. 4. Changes in expression of excitatory amino acid transporters (GLAST and GLT-1) in a
treatment, or treated with 50 μM Aβ 25–35 acutely or repeatedly as described under Materi
24 h after acute or the last repeated Aβ treatment. Quantiﬁcation of GLAST (b) and GLT-1 (c)
levels relative to the untreated controls (white bar) versus acute (gray bar) or repeated (blac
bands corresponding to the transporter. The Western blot in (a) is representative of two
(GLAST) and 3 (GLT-1) independent experiments. Numbers above the horizontal lines denoincreasing total Na+ concentration (Eqs. (6) and (7)). The corresponding
graph (Fig. 7) shows the dependence of total K+ concentration on total
Na+ concentration as the relative intracellular volume varies between
0 and 100%. Hence, at a theoretical zero intracellular cell volume, Na+
concentration is high while total K+ ion is low and corresponds to the
extracellular Na+ and K+ ion concentrations. Conversely, at a theoretical
zero extracellular volume,Na+ concentration is lowwhile K+ is high and
corresponds to the intracellular Na+ and [K+] ion concentrations.
The model predicts that the slope of the graph increases with in-
creasing intracellular cation concentrations (Fig. 7a and b). The lines
converge at the same point representing extracellular [Na+]=
147 mM and [K+]=2.8 mM and coincide with our experimentally
determined values for [Na+] and [K+] in CSF from normal individuals
and AD patients. The dotted lines in Fig. 7 correspond to intracellular
cation concentrations. As is evident from these plots, the slope is sen-
sitive to increases in intracellular [Na+] (Fig. 7a) or [K+] (Fig. 7b).
To assess how our experimentally derived data obtained in brain
ﬁt the model we plotted the tissue [K+] versus tissue [Na+] deter-
mined in each sample (Fig. 8). Data points representing control and
AD samples segregate to different areas in the graph. Interestingly,
despite the relatively small difference in the average ion concentra-
tions between cerebellar samples from AD versus controls, the data
points within each group also tended to segregate (Fig. 8). The linear
ﬁt for control (solid lines) and AD (dashed lines) data was obtained
by constraining the lines to intersect at the point with coordinates
of [Na+]=147 mmol/kg tissue and [K+]=2.8 mmol/kg tissue. The
ﬁtted lines display an excellent correspondence to the experimental
data points for the control set implying that individual variations in
total [Na+] and [K+] (ranging from 50 to 90 mmol/kg tissue [Na+]
and 89.0 to 49 mmol/kg tissue [K+]) result from variations in the
fractional intracellular volume (ranging from 0.71 to 0.42). In con-
trast, the linear ﬁt to the AD data has a signiﬁcantly higher slope
than the ﬁt to the control data in all three brain regions, consistent
with increased intracellular cation levels. The experimental data for
AD samples exhibit a much greater scatter than the control data.
This implies that in the AD samples, an additional source of individual
variations exist, which can be ascribed to variations in intracellular
cation concentrations.
The linear ﬁt to the control data for frontal cortex yields the fol-
lowing values for parameters representing the constant (A) and
slope (B) in Eq. (7): A=118 mM, B=−0.786. The same values for
these parameters can be obtained from Eqs. (8) and (9) using exper-
imentally derived extracellular cation concentrations and at intra-
cellular [Na+] and [K+] concentrations of 10 mM and 110 mM
respectively. Thus, the linear ﬁt coincides with the modeled plot in
Fig. 7, obtained for normal intracellular Na+ and K+ concentrations,
and supports the presence of normal intracellular cationstrocytes treated with Aβ 25–35. (a) Primary mouse astrocytes were cultured without
als and methods. Western blot analysis of GLAST and GLT-1 levels in the cells was done
Western blot data. The vertical bars represent the GLAST and GLT-1 protein expression
k bar) Aβ-treated cells. For GLT-1, the bars represent the sum of the intensity of the two
independent experiments and the data in (b) and (c) are mean±SEM obtained in 2
te the statistical signiﬁcance of the difference between the corresponding vertical bars.
Fig. 5. Cell-speciﬁc effect of Aβ 25–35 on intracellular cation levels. Intracellular levels of (a) Na+ and (b) K+ were measured in human astrocytoma cells, U-87MG, human embry-
onic kidney cells, HEK 293 and human T cell leukemia (Jurkat) cells. Ion concentrations were measured in untreated controls (white bars), or in cells acutely treated with 50 μM Aβ
25–35 (gray bars) after 24 h as described under Materials and methods. Cells were cultured and treated with Aβ 25–35 in 6-well plates at a cell density of 1–2×106 cells/well as
described under Materials and methods. Data represent the mean±SD; n=4 and 2 for control and Aβ treated U-87GM cells, n=8 and 4 for control and Aβ treated HEK 293 cells,
and n=4 and 2 for control and Aβ treated Jurkat cells respectively.
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cortex data yields the following parameter values: A=138, B=−
0.918. These values can be obtained from Eqs. (8) and (9) at intracel-
lular [Na+] and [K+] of 20 mM and 119 mM respectively. The plot of
the AD frontal cortex data reveals a signiﬁcant elevation in intracel-
lular cation concentrations. The estimates for intracellular cation con-
centrations for all three brain regions are shown in Table 4 and reveal
that the difference in cation concentrations between normal and AD
brain tissue samples canbe explainedby a signiﬁcant (two-fold) increase
in intracellular [Na+] together with a mild (8–15%) increase in intracel-
lular [K+]. Thus, analysis of our data obtained with postmortem brain
samples reveals a signiﬁcant increase in intracellular Na+ concentration
and amild increase in K+ concentration in AD compared to normal brain
samples. An obvious limitation of our study is that intracellular Na+ and
K+ concentrations cannot be measured directly in frozen postmortem
brain samples and we are unable to determine whether the ion imbal-
ance affects all or a subset of brain cell types. Direct measurement of
Na+ and K+ ion concentrations in AD brain samples is precluded by
loss of the transmembrane ion gradient in postmortem tissue.
A difference in glutamine and glutamate levels was not observed
between normal and AD brain samples (Table 2). It seems unlikely
that the use of postmortem tissue obscured possible changes in
these amino acid pool sizes since previous reports indicate that gluta-
mine and glutamate levels in brain do not change signiﬁcantly up to
48 h postmortem [32,33]. On the other hand, methionine increased
signiﬁcantly in postmortem brain tissue from ~10–50 μmol/kg of tis-
sue up to 230 μmol/kg of tissue [32,33]. Hence, the observedFig. 6. The effect of Aβ 1–40 on intracellular levels of Na+ and K+ in primary mouse astro
treated with 10 or 50 μM of Aβ 1–40 (black bars). Intracellular Na+ (a) and K+ (b) levels
Data represent the mean±SD of two independent experiments each performed in triplicate
tween corresponding vertical bars.difference in methionine levels between normal and AD cerebellum
(Table 2) might be related to postmortem methionine accumulation.
We used a cell culture model to assess whether the ion perturbations
observed in AD brain samples might be associated with Aβ. Since Aβ in-
duces neuronal death in vitro, it precluded their use in the current exper-
imental protocols, which involve a prolonged exposure of cells to Aβ.
Instead, we used astrocytes and primarily, the synthetic Aβ 25–35 pep-
tide. While this peptide is generally considered to be unnatural, there is
evidence of its presence in AD brain [34,35]. Its greater affordability has
resulted in the widespread use of the Aβ 25–35 peptide as a surrogate
for the naturally occurring Aβ 1–40/42 peptides, particularly since it
often elicits very similar effects [36–41]. We note a further caveat
i.e., that while the sequences of the human andmurine Aβ 25–35 peptide
are identical, the sequences of the longer Aβ 1–40/42 peptides are not,
raising some questions about the use of the commercially available
humanAβ1–40/42peptide sequence in ex vivo experimentswithmurine
cells. We note that the Aβ concentration used in our experiments is esti-
mated basedon the initial concentration of soluble peptide prior to aggre-
gation. The presence of residual soluble Aβ (monomer, oligomer) in these
preparations cannot be ruled out. While the 50 μM Aβ concentration
used in our cell culturemight be considered to behigh, inAlzheimer's dis-
ease, cells are exposed to Aβ in soluble and aggregate form over a period
of many years. We speculate that prolonged exposure of tissue to lower
Aβ concentrationsmight elicit some of the same effects as short term ex-
posure to higher Aβ concentrations in cell culture experiments.
Interestingly, in our study, the Aβ 1–40 like the Aβ 25–35 peptide
induced astrocytic ion imbalance while Aβ 1–42 had no effect. Acytes. Cells were cultured without Aβ treatment (control, white bars) or were acutely
were measured 24 h after Aβ treatment as described under Materials and methods.
. Numbers above the horizontal lines show statistical signiﬁcance of the difference be-
Fig. 7.Modeled dependence of total tissue potassium concentration on total tissue sodium concentration in samples with different relative intracellular volumes. Graphs were plot-
ted using Eqs. (3) and (4) at extracellular [Na+]=147 mM and [K+]=2.8 mM and (a) at intracellular Kin=110 mM and intracellular Nain of 5, 10, 20, and 40 mM, and (b) at in-
tracellular Nain=10 mM and intracellular Kin of 100, 110, 120, and 130 mM. Symbols indicate data points with different relative intracellular volumes from 1.0 to 0.0 in 0.1
increments. The point with the lowest Kt value and highest Nat value corresponds to extracellular [Na+]=147 mM and [K+]=2.8 mM (relative intracellular volume=0.0). The
points with the highest Kt values show intracellular concentrations of Na+ and K+ when the relative intracellular volume=1.0.
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1–42 has been reported in a studywhere Aβ 25–35 and Aβ 1–42 caused
signiﬁcant activation of glucose consumption in astrocytes while Aβ
1–40 had no effect [37]. These results demonstrate that even a small dif-
ference in the length of the Aβ peptide can be associated with a signif-
icant difference in the effects that it elicits warranting caution about
results obtained with these peptides. Further, we note that the effects
of Aβ 1–40 and Aβ 1–42 on ion concentrations in astrocytes wereFig. 8. Comparison of Na+ and K+ ion concentrations in brain tissue from AD patients
versus matched controls. Na+ and K+ ion concentrations were measured in brain ho-
mogenates of frontal cortex (FC), parietal cortex (PC) and cerebellum (Cb) from AD
(open circles, n=16) and normal (control) (black circles, n=12) subjects. Data were
normalized to the amount of tissue. Symbols show individual data and the solid and
dashed lines represent the linear ﬁts to the control and AD data points, respectively.only studied under conditions of acute treatment. Our studies with Aβ
25–35 show that repeated treatment can elicit signiﬁcantly larger ef-
fects on ion levels than acute treatment (Figs. 1, 2a). Hence, our data
do not allow us to exclude the possibility that repeated exposure of
brain cells to Aβ 1–42 might also elicit ion imbalance.
Our experimentswith cultured astrocytes reveal that both acute and
repeated treatmentswith Aβ 25–35 cause a signiﬁcant increase in intra-
cellular levels of Na+ and K+ that is associated with reduced levels of
the Na+/K+ ATPase, the Na+-dependent glutamate transporters, and
as previously reported, the glutamate/cystine antiporter [15]. However,
the observed ion imbalance (i.e. the simultaneous increase in Na+ and
K+ levels in cells) cannot be explained by a decrease in these transport-
er levels. Additionally, the Na/K/Cl co-transporter(s) and Na/H ex-
changer(s) do not appear to be involved in the molecular mechanism
of Aβ-induced astrocytic Na+ and K+ imbalances.
Aβ is known to inﬂuence the permeability of biological mem-
branes [42]. A decrease in astrocytic Kir4.1 (an inward rectifying po-
tassium channel) and the BK channel (a calcium sensitive large
conductance potassium channel) has been reported in mouse AD
models and in human tissue [43]. While perturbations in the trans-
port and levels of Ca2+ and some transitionmetal ions in AD brain tis-
sue and Aβ treated cells have been studied [42,44,45], changes in Na+
and K+ have received little if any attention. To our knowledge, this is
the ﬁrst demonstration that Aβ can cause an imbalance in Na+ and
K+ levels in astrocytes and the underlying molecular mechanism of
this Aβ-induced imbalance warrants further investigation.
Interestingly, the increase in Na+ and K+ levels observed in cul-
tured Aβ-treated astrocytes is comparable to the estimated increases
in intracellular Na+ and K+ concentrations in AD brain tissue,
suggesting the possibility that Aβ also causes Na+ and K+ imbalances
in AD brain cells. Other cell types in brain (neurons, oligodendrocytes
and microglia) might also play a role in total Na+ and K+ imbalances
in AD brain tissue. We note that while Na+ and K+ imbalances in AD
brain appears to be related to Aβ, our study does not address whether
this is a speciﬁc feature of AD pathology that is not associated with
other diseases, such as schizophrenia, dementia or autism, and merits
investigation.
An increase in intracellular ion concentrations is expected to have
widespread ramiﬁcations on cellular functions ranging from transport
to ion conductance and intercellular signaling. An increase in intracellu-
lar Na+ concentration is expected to inhibit the Na+/Ca2+ exchanger
leading to accumulation of intracellular Ca2+ that, in turn, can stimulate
multiple signaling pathways, including cell death initiation [46]. Mem-
brane depolarization caused by a signiﬁcant ion imbalance in brain is
associated with such pathologies as migraine, stroke, and traumatic
brain injury [47]. These disturbances are likely to contribute to neuronal
Table 4
Estimates of intracellular N+ and K+ concentrations in AD versus control brain
samples.a
Parameter Subject Frontal cortex Parietal cortex Cerebellum
Ab (mM) Normal 118 120 126
AD 138 148 157
Bc Normal −0.786 −0.797 −0.838
AD −0.918 −0.986 −0.1.049
Nain (mM) Normal 10 10 10
AD 20 20 20
Kind (mM) Normal 110 112 118
AD 119 128 136
a The values in this table are obtained from ﬁts to the data shown in Fig. 8.
b Parameter A represents a constant in Eq. (7) and is deﬁned in Eq. (8) as described
under Materials and methods.
c Parameter B represents the slope of the graph in Eq. (7) and is deﬁned in Eq. (9) as
described under Materials and methods.
d Estimates of intracellular K+ concentration in control and AD tissue were obtained
from the slope of the ﬁtted line using Eq. (9) and assuming that the corresponding in-
tracellular Na+ concentration is 10 mM and 20 mM for control and AD tissue
respectively.
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ability [48], and might trigger cell death pathways contributing to the
degeneration and atrophy seen in AD brain. A decreased transmem-
brane Na+ gradient in astrocytes might be one factor leading to a de-
crease in glutamate clearance capacity in AD brain. The dramatic
decrease in GLAST andGLT-1 protein expression observed in repeatedly
Aβ-treated astrocytes if replicated in AD brain, would predict distur-
bances in synaptic signal transmission. Furthermore, since the trans-
membrane sodium gradient serves as a driving force for the active
transport of many amino acids into cells, dissipation of this gradient
would elicit pleiotropic metabolic and physiological dysfunction. On
the other hand, the steeper transmembrane K+ gradient observed in
Aβ treated astrocytes if replicated in AD brain, would predict inhibition
of uptake of K+ released by neurons during the repolarization phase of
action potentials [16], affecting neuronal electrophysiological activity.5. Conclusions
Perturbations of Na+ and K+ ion pools, critical for electrophysio-
logical activity, membrane transport, and other cellular processes,
are largely unstudied in AD. Our demonstration that Aβ application
elicits profound increases in both intracellular Na+ and K+ concen-
trations in cultured astrocytes similar to changes in the Na+ and K+
pools found in post-mortem tissues from AD brain, suggests aberra-
tions in a fundamental homeostatic mechanism that might be impor-
tant in the pathophysiology of this neurodegenerative disease.
Furthermore, our results demonstrate that while the cerebellum is
considered to be unaffected in AD brain, we see evidence for cation
imbalance in this region.Acknowledgements
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